AIM: To define the biological nature and malignant potential of interval cancers presenting to a breast unit within the NHS breast screening programme. METHODS: 112 interval cancers were compared with matched, screen detected and symptomatic cancers in terms of their radiographic, histopathological, and immunohistochemical features. RESULTS: Interval cancers, strictly defined, showed no characteristic radiographic pattern. In terms of size, vascular invasion, lymph node status, and prognosis they were intermediate between screen detected and symptomatic cancers. Within the interval cancers there was an excess of grade 1 and grade 3 tumours, and lesions with a high Ki67 index but immunohistochemistry otherwise failed to discriminate between the three groups. Inclusion of data from false negative "interval cancers" did not significantly alter the results. CONCLUSIONS: Interval cancers are more aggressive than screen detected cancers but in general less aggressive than symptomatic cancers. However, within a heterogeneous group, occasional interval cancers are exceptionally malignant.
AIM: To define the biological nature and malignant potential of interval cancers presenting to a breast unit within the NHS breast screening programme. METHODS: 112 interval cancers were compared with matched, screen detected and symptomatic cancers in terms of their radiographic, histopathological, and immunohistochemical features. RESULTS:Interval cancers, strictly defined, showed no characteristic radiographic pattern. In terms of size, vascular invasion, lymph node status, and prognosis they were intermediate between screen detected and symptomatic cancers. Within the interval cancers there was an excess of grade 1 and grade 3 tumours, and lesions with a high Ki67 index but immunohistochemistry otherwise failed to discriminate between the three groups. Inclusion of data from false negative "interval cancers" did not significantly alter the results. CONCLUSIONS:Interval cancers are more aggressive than screen detected cancers but in general less aggressive than symptomatic cancers. However, within a heterogeneous group, occasional interval cancers are exceptionally malignant.
Authors: C Wright; B Angus; S Nicholson; J R Sainsbury; J Cairns; W J Gullick; P Kelly; A L Harris; C H Horne Journal: Cancer Res Date: 1989-04-15 Impact factor: 12.701
Authors: J L Haybittle; R W Blamey; C W Elston; J Johnson; P J Doyle; F C Campbell; R I Nicholson; K Griffiths Journal: Br J Cancer Date: 1982-03 Impact factor: 7.640
Authors: Anna M Chiarelli; Kristina M Blackmore; Lucia Mirea; Susan J Done; Vicky Majpruz; Ashini Weerasinghe; Linda Rabeneck; Derek Muradali Journal: J Natl Cancer Inst Date: 2020-04-01 Impact factor: 13.506
Authors: Mark E Sherman; Jonine D Figueroa; Jill E Henry; Susan E Clare; Connie Rufenbarger; Anna Maria Storniolo Journal: Cancer Prev Res (Phila) Date: 2012-02-17
Authors: Patricia A Carney; Elizabeth Steiner; Martha E Goodrich; Allen J Dietrich; Claudia J Kasales; Julia E Weiss; Todd MacKenzie Journal: Ann Fam Med Date: 2006 Nov-Dec Impact factor: 5.166
Authors: L Provencher; J C Hogue; C Desbiens; B Poirier; E Poirier; D Boudreau; M Joyal; C Diorio; N Duchesne; J Chiquette Journal: Curr Oncol Date: 2016-08-12 Impact factor: 3.677
Authors: Cheryl Lin; Meredith Becker Buxton; Dan Moore; Helen Krontiras; Lisa Carey; Angela DeMichele; Leslie Montgomery; Debasish Tripathy; Constance Lehman; Minetta Liu; Olufunmilayo Olapade; Christina Yau; Donald Berry; Laura J Esserman Journal: Breast Cancer Res Treat Date: 2011-07-28 Impact factor: 4.872
Authors: Mia M Gaudet; Emily Deubler; W Ryan Diver; Samantha Puvanesarajah; Alpa V Patel; Ted Gansler; Mark E Sherman; Susan M Gapstur Journal: Breast Cancer Res Treat Date: 2021-01-04 Impact factor: 4.872
Authors: Jan T Lowery; Tim Byers; John Kittelson; John E Hokanson; Judy Mouchawar; John Lewin; Dan Merrick; Lisa Hines; Meenakshi Singh Journal: Breast Cancer Res Treat Date: 2011-03-24 Impact factor: 4.872